Democrats to push for generic biotech drugs

A Democratic victory at the polls is likely to lead to new legislation that finally paves the way to generic biologics, or biosimilars. This is one of the hottest issues in the biotech business, and one that's likely to draw fierce opposition from the industry groups lobbying Congress. Until now, biotech has held sway with its argument that biotech drugs are too complex to allow for generic knockoffs. But as Europe has moved toward sanctioning biosimilars, the U.S. probably isn't that far behind. A group of leading Democrats who will wield significant power in the next Congress are outspoken supporters of new generic legislation. And with the Party's focus on cutting drug costs while expanding government programs, analysts say that Congress may well have reached a critical tipping point.

- here's the article from The Los Angeles Times for more

Related Articles:
Legislation could clear way for biosimilars. Report
Drug stocks damaged by Democrats' success. Report
Democratic win could be bad news for pharma industry. Report
Generic competition heats up. Report